• Citer

A gene signature to predict high tumour-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple negative breast cancer.

par Criscitiello, Carmen ;Bayar, M.A.;Curigliano, Giuseppe;Symmans, Fraser;Desmedt, Christine ;Bonnefoi, Herve;Sinn, B;Pruneri, Giancarlo;Vicier, C;Pierga, Jean-Yves;Denkert, Carsten;Loibl, Sibylle;Sotiriou, Christos ;Michiels, Stefan ;Andre, Fabrice
Référence Annals of oncology
Publication Publié, 2017-10

Article révisé par les pairs

• Détails
• Contenu

Résumé :

In patients with triple-negative breast cancer (TNBC), the extent of tumor-infiltrating lymphocytes (TILs) in the residual disease (RD) after neoadjuvant chemotherapy (NACT) is associated with better prognosis. Our objective was to develop a gene signature from pre-treatment samples to predict the extent of TILs after NACT, and then to test its prognostic value on survival.